Open AccessThe use of regorafenib in colorectal cancer
Author(s) -
Marina Sekacheva,
Секачева Марина Игоревна,
Н Н Багмет,
Багмет Николай Николаевич,
Anastasia A. Guryanova,
Гурьянова Анастасия Андреевна,
Diana Al' Rashi,
Аль Раши Диана Омаровна
Publication year - 2019
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/18151434.2019.2.190416
Subject(s) - regorafenib , colorectal cancer , medicine , irinotecan , oncology , kras , oxaliplatin , cancer , cetuximab , cancer research
Colorectal cancer is the third most common type of cancer in men and the second in women worldwide. The data demonstrate the increase in the annual incidence of colorectal cancer, but still the significant number of patients is detected having late-stage cancer. Regorafenib is an oral multi-kinase inhibitor that targets kinases VEGF1, VEGF2, VEGF3, PDGFR, and FGFR involved in the regulation of tumor angiogenesis, and KIT, RET, RAF-1, BRAF involved in oncogenesis. The application of regorafenib has shown statistically significant increase of progression-free survival and overall survival, thus regorafenib been approved for the treatment of metastatic colorectal cancer, associated with resistance to fluoropyrimidine, oxaliplatin or irinotecan-based therapy in combination with the VEGR inhibitor and anti-EGFR-antibodies in patients with wild type KRAS gene. The article deals with the results of major studies carried out to explore the characteristics and efficacy and safety evaluation of regorafenib. We have analyzed in the review the results of recent studies on changes in indicators of overall survival, progression-free survival, and the efficacy of regorafenib therapy, safety and objective response.